GENENTA SCIENCE(SP.ADR)/1 - Asset Resilience Ratio
GENENTA SCIENCE(SP.ADR)/1 (K5F) has an Asset Resilience Ratio of 70.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read K5F current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how GENENTA SCIENCE(SP.ADR)/1's Asset Resilience Ratio has changed over time. See GENENTA SCIENCE(SP.ADR)/1 book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down GENENTA SCIENCE(SP.ADR)/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GENENTA SCIENCE(SP.ADR)/1 (K5F) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €22.62 Million | 70.94% |
| Total Liquid Assets | €22.62 Million | 70.94% |
Asset Resilience Insights
- Very High Liquidity: GENENTA SCIENCE(SP.ADR)/1 maintains exceptional liquid asset reserves at 70.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GENENTA SCIENCE(SP.ADR)/1 Industry Peers by Asset Resilience Ratio
Compare GENENTA SCIENCE(SP.ADR)/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Crispr Therapeutics AG
NASDAQ:CRSP |
Biotechnology | 74.05% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
Annual Asset Resilience Ratio for GENENTA SCIENCE(SP.ADR)/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for GENENTA SCIENCE(SP.ADR)/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.94% | €22.62 Million ≈ $26.45 Million |
€31.89 Million ≈ $37.28 Million |
+16.44pp |
| 2024-12-31 | 54.49% | €8.08 Million ≈ $9.44 Million |
€14.82 Million ≈ $17.33 Million |
-13.01pp |
| 2023-12-31 | 67.50% | €15.08 Million ≈ $17.64 Million |
€22.35 Million ≈ $26.13 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€33.44 Million ≈ $39.09 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€40.03 Million ≈ $46.80 Million |
-- |
About GENENTA SCIENCE(SP.ADR)/1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more